Aspirin reduces adverse effects of gefitinib

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 423-427

  Kanazawa, Shigenori ^a   Yamaguchi, Kazuyuki ^a   Kinoshita, Yoshimi ^a   Muramatsu, Mikiko ^a   Komiyama, Yutaka ^a   Nomura, Shosaku ^a,b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

Aspirin; Complication; Gefitinib; P selectin; TxB2

Indexed keywords

ACETYLSALICYLIC ACID; GEFITINIB; PADGEM PROTEIN; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; EPISTAXIS; FEMALE; HUMAN; LOW DRUG DOSE; LUNG CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SKIN DEFECT; SOLUBILITY; THROMBOCYTE ACTIVATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG INTERACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; QUINAZOLINES; THROMBOXANE B2;

EID: 33748185279     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000203385.45163.76     Document Type: Article

References (12)

1. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92:1175-1181.
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
3. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-250.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
5. Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003; 40:339-342.
6. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
7. Kanazawa S, Muramatsu M, Kinoshita Y, Yamaguchi K, Nomura S. Gefitinib has the potential of activating cell immunity against malignant cells. J Clin Oncol 2005; 23:3865-3866.
8. Yamaguchi K, Kanazawa S, Kinoshita Y, Muramatsu N, Nomura S. Elevation of plasma RANTES levels and prognosis in patients treated with gefitinib. J Clin Oncol 2005; 23 (Suppl):244s.
9. Wells A. Molecules in focus EGFR receptor. Int J Biochem Cell Biol 1999; 31:637-643.
10. Normanno N, Di Maio M, Perrone F. Molecular markers to predict response to gefitinib: EGFR, ErbB2, or more? J Clin Oncol 2004; 22:2035-2036.
11. Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S. Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. Clin Appl Thromb Hemost 2005; 11:429-435.
12. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176:587-592.